Gateway Wealth Partners LLC Buys New Shares in ARK Genomic Revolution ETF $ARKG

Gateway Wealth Partners LLC bought a new position in shares of ARK Genomic Revolution ETF (BATS:ARKG) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 13,222 shares of the company’s stock, valued at approximately $349,000.

A number of other large investors have also bought and sold shares of the stock. NewEdge Advisors LLC raised its holdings in shares of ARK Genomic Revolution ETF by 49.4% during the first quarter. NewEdge Advisors LLC now owns 5,384 shares of the company’s stock valued at $112,000 after purchasing an additional 1,780 shares during the period. Creative Planning acquired a new stake in shares of ARK Genomic Revolution ETF in the 2nd quarter valued at about $255,000. Baird Financial Group Inc. grew its stake in shares of ARK Genomic Revolution ETF by 81.0% in the 2nd quarter. Baird Financial Group Inc. now owns 71,977 shares of the company’s stock valued at $1,753,000 after buying an additional 32,221 shares during the period. Strategic Wealth Investment Group LLC bought a new stake in ARK Genomic Revolution ETF in the 2nd quarter valued at about $38,000. Finally, Group One Trading LLC bought a new stake in ARK Genomic Revolution ETF in the 2nd quarter valued at about $2,274,000.

ARK Genomic Revolution ETF Stock Down 1.8%

ARKG stock opened at $38.56 on Friday. The stock’s 50 day simple moving average is $37.71 and its 200 day simple moving average is $32.16. ARK Genomic Revolution ETF has a fifty-two week low of $22.73 and a fifty-two week high of $44.47.

ARK Genomic Revolution ETF Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.